Literature DB >> 34315207

Management of Parkinson's Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination.

Yue Hui Lau1, Keng Ming Lau2, Norlinah Mohamed Ibrahim3.   

Abstract

The current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) has led to a serious global health crisis. Increasing evidence suggests that elderly individuals with underlying chronic diseases, including Parkinson's disease (PD), are particularly vulnerable to this infection. Changes in the routine care of PD patients should be implemented carefully without affecting the quality provided. The utilization of telemedicine for clinical consultation, assessment and rehabilitation has also been widely recommended. Therefore, the aim of this review is to provide recommendations in the management of PD during the pandemic as well as in the early phase of vaccination programs to highlight the potential sequelae and future perspectives of vaccination and further research in PD. Even though a year has passed since COVID- 19 emerged, most of us are still facing great challenges in providing a continuum of care to patients with chronic neurological disorders. However, we should regard this health crisis as an opportunity to change our routine approach in managing PD patients and learn more about the impact of SARS-CoV-2. Hopefully, PD patients can be vaccinated promptly, and more detailed research related to PD in COVID-19 can still be carried out.

Entities:  

Keywords:  COVID-19; Future perspective; Parkinson’s disease; SARS-CoV-2; Vaccination

Year:  2021        PMID: 34315207     DOI: 10.14802/jmd.21034

Source DB:  PubMed          Journal:  J Mov Disord        ISSN: 2005-940X


  5 in total

Review 1.  Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.

Authors:  Jeremy M Morowitz; Kaylyn B Pogson; Daniel A Roque; Frank C Church
Journal:  Brain Sci       Date:  2022-04-22

2.  Covid-19 and Parkinson's disease: Nursing care, vaccination and impact on advanced therapies.

Authors:  Anna Roszmann; Aleksandra M Podlewska; Yue Hui Lau; Iro Boura; Annette Hand
Journal:  Int Rev Neurobiol       Date:  2022-07-09       Impact factor: 4.280

Review 3.  Impact of Covid-19 on research and training in Parkinson's disease.

Authors:  Yi-Min Wan; Daniel J van Wamelen; Yue Hui Lau; Silvia Rota; Eng-King Tan
Journal:  Int Rev Neurobiol       Date:  2022-05-04       Impact factor: 4.280

Review 4.  Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson's Disease Affected by COVID-19: A Narrative Review.

Authors:  Jasjit S Suri; Mahesh A Maindarkar; Sudip Paul; Puneet Ahluwalia; Mrinalini Bhagawati; Luca Saba; Gavino Faa; Sanjay Saxena; Inder M Singh; Paramjit S Chadha; Monika Turk; Amer Johri; Narendra N Khanna; Klaudija Viskovic; Sofia Mavrogeni; John R Laird; Martin Miner; David W Sobel; Antonella Balestrieri; Petros P Sfikakis; George Tsoulfas; Athanase D Protogerou; Durga Prasanna Misra; Vikas Agarwal; George D Kitas; Raghu Kolluri; Jagjit S Teji; Mustafa Al-Maini; Surinder K Dhanjil; Meyypan Sockalingam; Ajit Saxena; Aditya Sharma; Vijay Rathore; Mostafa Fatemi; Azra Alizad; Padukode R Krishnan; Tomaz Omerzu; Subbaram Naidu; Andrew Nicolaides; Kosmas I Paraskevas; Mannudeep Kalra; Zoltán Ruzsa; Mostafa M Fouda
Journal:  Diagnostics (Basel)       Date:  2022-06-24

Review 5.  Viruses, parkinsonism and Parkinson's disease: the past, present and future.

Authors:  Valentina Leta; Daniele Urso; Lucia Batzu; Yue Hui Lau; Donna Mathew; Iro Boura; Vanessa Raeder; Cristian Falup-Pecurariu; Daniel van Wamelen; K Ray Chaudhuri
Journal:  J Neural Transm (Vienna)       Date:  2022-08-29       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.